Heterogeneity and Adjuvant Therapeutic Approaches in MSI-H/dMMR Resectable Gastric Cancer: Emerging Trends in Immunotherapy

Overview

Journal Ann Surg Oncol

Publisher Springer

Specialty Oncology

Date 2023 Sep 4

PMID 37667098

Authors

Hui Wu

Wenyuan Ma

Congfa Jiang

Ning Li

Xin Xu

Yongfeng Ding

Haiping Jiang

Affiliations

Soon will be listed here.

Abstract

Gastric cancer (GC) remains one of the world's most common and fatal malignant tumors. With a refined understanding of molecular typing in recent years, microsatellite instability (MSI) has become a major molecular typing approach for gastric cancer. MSI is well recognized for its important role during the immunotherapy of advanced GC. However, its value remains unclear in resectable gastric cancer. The reported incidence of microsatellite instability-high (MSI-H)/deficient mismatch repair (dMMR) in resectable gastric cancer varies widely, with no consensus reached on the value of postoperative adjuvant therapy in patients with MSI-H/dMMR resectable GC. It has been established that MSI-H/dMMR tumor cells can elicit an endogenous immune antitumor response and ubiquitously express immune checkpoint ligands such as PD-1 or PD-L1. On the basis of these considerations, MSI-H/dMMR resectable GCs are responsive to adjuvant immunotherapy, although limited research has hitherto been conducted. In this review, we comprehensively describe the differences in geographic distribution and pathological stages in patients with MSI-H/dMMR with resectable gastric cancer and explore the value of adjuvant chemotherapy and immunotherapy on MSI-H/dMMR to provide a foothold for the individualized treatment of this patient population.

Citing Articles

Liquid biopsy in gastric cancer: A snapshot of the current state of the art.

Gasparello J, Ceccon C, Angerilli V, Comunello T, Sabbadin M, DAlmeida Costa F J Liq Biopsy. 2025; 7:100288.

PMID: 40027230 PMC: 11863821. DOI: 10.1016/j.jlb.2025.100288.

DNA methyltransferase 3A: A prognostic biomarker and potential target for immunotherapy in gastric cancer.

Wei Z, Kou Z, Luo Y, Cheng Y Medicine (Baltimore). 2025; 104(7):e41578.

PMID: 39960919 PMC: 11835108. DOI: 10.1097/MD.0000000000041578.

Evolving Strategies in the Management of Microsatellite Instability-High/Mismatch Repair Deficient Esophagogastric Adenocarcinoma.

Balmaceda N, Kim S Curr Oncol Rep. 2025; 27(2):81-94.

PMID: 39832053 DOI: 10.1007/s11912-024-01624-4.

Successful conversion surgery after comprehensive therapy in a patient with MSI-H but pMMR metastatic gastric mixed adenoneuroendocrine carcinoma: a case report and literature review.

He J, Wang L, Tuo C, Gong W, Liu Y Front Oncol. 2024; 14:1463884.

PMID: 39723386 PMC: 11668672. DOI: 10.3389/fonc.2024.1463884.

Immunotherapy for metastatic gastric cancer.

Li C, Lian L, Li Q, Jiao Y World J Gastrointest Surg. 2024; 16(11):3408-3412.

PMID: 39649204 PMC: 11622096. DOI: 10.4240/wjgs.v16.i11.3408.

References

Choi Y, Kim H, Shin S, Kim H, Lee J, Yang H . Microsatellite Instability and Programmed Cell Death-Ligand 1 Expression in Stage II/III Gastric Cancer: Post Hoc Analysis of the CLASSIC Randomized Controlled study. Ann Surg. 2018; 270(2):309-316. DOI: 10.1097/SLA.0000000000002803. View

Choi J, Nam S, Park D, Kim H, Kim H, Kim W . Correlation between microsatellite instability-high phenotype and occult lymph node metastasis in gastric carcinoma. APMIS. 2015; 123(3):215-22. DOI: 10.1111/apm.12345. View

Shitara K, Van Cutsem E, Bang Y, Fuchs C, Wyrwicz L, Lee K . Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020; 6(10):1571-1580. PMC: 7489405. DOI: 10.1001/jamaoncol.2020.3370. View

Baretti M, Le D . DNA mismatch repair in cancer. Pharmacol Ther. 2018; 189:45-62. DOI: 10.1016/j.pharmthera.2018.04.004. View

Palli D, Russo A, Saieva C, Salvini S, Amorosi A, Decarli A . Dietary and familial determinants of 10-year survival among patients with gastric carcinoma. Cancer. 2000; 89(6):1205-13. DOI: 10.1002/1097-0142(20000915)89:6<1205::aid-cncr3>3.0.co;2-5. View

Lei Z, Tan I, Das K, Deng N, Zouridis H, Pattison S . Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil. Gastroenterology. 2013; 145(3):554-65. DOI: 10.1053/j.gastro.2013.05.010. View

Smyth E, Wotherspoon A, Peckitt C, Gonzalez D, Hulkki-Wilson S, Eltahir Z . Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial. JAMA Oncol. 2017; 3(9):1197-1203. PMC: 5824280. DOI: 10.1001/jamaoncol.2016.6762. View

Raimondi A, Palermo F, Prisciandaro M, Aglietta M, Antonuzzo L, Aprile G . TremelImumab and Durvalumab Combination for the Non-OperatIve Management (NOM) of Microsatellite InstabiliTY (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study. Cancers (Basel). 2021; 13(11). PMC: 8201030. DOI: 10.3390/cancers13112839. View

An J, Kim H, Cheong J, Hyung W, Kim H, Noh S . Microsatellite instability in sporadic gastric cancer: its prognostic role and guidance for 5-FU based chemotherapy after R0 resection. Int J Cancer. 2011; 131(2):505-11. DOI: 10.1002/ijc.26399. View

10.

Cong Nie R, Chen G, Yuan S, Kim J, Zhou J, Nie M . Correction to: Adjuvant Chemotherapy for Gastric Cancer Patients with Mismatch Repair Deficiency or Microsatellite Instability: Systematic Review and Meta-Analysis. Ann Surg Oncol. 2021; 29(5):3193. DOI: 10.1245/s10434-021-11151-2. View

11.

Kim J, Shin N, Kim A, Lee H, Park W, Kim J . Microsatellite instability status in gastric cancer: a reappraisal of its clinical significance and relationship with mucin phenotypes. Korean J Pathol. 2013; 47(1):28-35. PMC: 3589606. DOI: 10.4132/KoreanJPathol.2013.47.1.28. View

12.

Solcia E, Klersy C, Mastracci L, Alberizzi P, Candusso M, Diegoli M . A combined histologic and molecular approach identifies three groups of gastric cancer with different prognosis. Virchows Arch. 2009; 455(3):197-211. DOI: 10.1007/s00428-009-0813-z. View

13.

Koopman M, Kortman G, Mekenkamp L, Ligtenberg M, Hoogerbrugge N, Antonini N . Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer. 2009; 100(2):266-73. PMC: 2634718. DOI: 10.1038/sj.bjc.6604867. View

14.

Sargent D, Marsoni S, Monges G, Thibodeau S, Labianca R, Hamilton S . Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010; 28(20):3219-26. PMC: 2903323. DOI: 10.1200/JCO.2009.27.1825. View

15.

Cristescu R, Lee J, Nebozhyn M, Kim K, Ting J, Wong S . Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med. 2015; 21(5):449-56. DOI: 10.1038/nm.3850. View

16.

Schneider B, Bravo J, Roa J, Roa I, Kim M, Lee K . Microsatellite instability, prognosis and metastasis in gastric cancers from a low-risk population. Int J Cancer. 2000; 89(5):444-52. DOI: 10.1002/1097-0215(20000920)89:5<444::aid-ijc8>3.0.co;2-f. View

17.

Kim K, Lee T, Cho N, Yang H, Kim W, Kang G . Differential clinicopathologic features in microsatellite-unstable gastric cancers with and without MLH1 methylation. Hum Pathol. 2012; 44(6):1055-64. DOI: 10.1016/j.humpath.2012.09.009. View

18.

Lee H, Chae S, Lee Y, Kim M, Lee H, Lee B . Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer. Br J Cancer. 2008; 99(10):1704-11. PMC: 2584941. DOI: 10.1038/sj.bjc.6604738. View

19.

Fang W, Chang S, Lan Y, Huang K, Chen J, Lo S . Microsatellite instability is associated with a better prognosis for gastric cancer patients after curative surgery. World J Surg. 2012; 36(9):2131-8. DOI: 10.1007/s00268-012-1652-7. View

20.

Andre T, Tougeron D, Piessen G, De La Fouchardiere C, Louvet C, Adenis A . Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study. J Clin Oncol. 2022; 41(2):255-265. PMC: 9839243. DOI: 10.1200/JCO.22.00686. View